HomeProductsBioactive CompoundsCytoskeletonIntegrinZalunfiban
Chemical structure of CAS 1448313-27-6

Zalunfiban

CAS No.1448313-27-6
MDL No.N/A
MFC16H18N8O2S
MW386.40
InChI KeyLTVKZVGAALCRFW-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1448313-27-6
Product NameZalunfiban

Biological Targets

ITGB3·ITGA2B

Associated Conditions

coronary artery disease·ST Elevation Myocardial Infarction
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology • Vol. 17, Issue 5 • 2021
PMID: 34031019PMC: PMC9464482DOI: 10.4244/EIJ-D-21-00287

Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets.

Journal of clinical and translational science • Vol. 3, Issue 2-3 • 2019
PMID: 31544007PMC: PMC6753935DOI: 10.1017/cts.2019.382

RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction.

Arteriosclerosis, thrombosis, and vascular biology • Vol. 34, Issue 10 • 2014
PMID: 25147334PMC: PMC4180209DOI: 10.1161/ATVBAHA.114.303724

A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor.

Bioorganic & medicinal chemistry letters • Vol. 24, Issue 4 • 2014
PMID: 24461295PMC: PMC3951875DOI: 10.1016/j.bmcl.2013.12.122

Documentation

Similar Products